I am very proud to be speaking at two events. The luncheons are hosted by Family Office Networks. Hence, I am presenting both presentations regarding how my company, Advanced Bifurcation Systems has created the only stenting technology that will cover all types of bifurcations.
The first engagement is on September 27th at The Barrel Room in San Francisco. The topic is the Paradigm Shift in Interventional Cardiology. You can RSVP here.
Likewise, the second engagement is on October 17th at Lucques in West Hollywood. In turn, the topic for this one is Bifurcation Disease for a Disruptive Technology; How the Mother-Daughter Solution for all bifurcations. You may RSVP here.
Proud to Have Dick Cheney With Us
We are very much looking forward to our exhibit at the tct2018 convention in San Diego. My company Advanced Bifurcation Systems is proud to have Dick Cheney join us at our booth.
The convention is put on by the Cardiovascular Research Foundation. Located at the San Diego Convention Center on September 21st through the 25th.
CVD is the Worlds Leading Killer…By Far
Cardiovascular disease is our number one public health challenge and more people die annually from CVDs than from any other cause. The World Health Organization estimates that 17.7 million people died from CVDs in 2015. This is nearly third of all global deaths. This includes an estimated 7.4 million deaths from coronary heart disease and 6.7 million from stroke.
Innovation Is the engine for Change and Investors and Entrepreneur provide the Fuel and Spark
Advanced Bifurcation Systems has developed a novel, potentially revolutionary mother-daughter coronary stenting platform that has the potential to reduce the duration of stenting procedures, improve the reliability of bifurcation disease stenting and simplify the procedure for practitioners. So I am presenting at noon this Thursday, August 23rd in at the 2018 Southern California Investor Conference. The conference will be at the Balboa Bay Resort in Newport Beach. I am expecting up to 300 investors will come and hear about the opportunity.
Analysts report that the coronary stent market is expected to reach $10B in 2025. Bifurcation disease could be about 25% of this market. ABS represents a great opportunity for family office investors who seek to make a real impact on the future of healthcare. So as Family Office Networks Founder Andrew Schneider recently put it, “We believe ABS is poised to capture a significant part of this $2.5B market as the only true and complete bifurcating stent delivery platform in the market.”
I hope you will join us
Thursday, August 23rd
Balboa Bay Resort, Newport Beach
Livermore, California Selected As Our First Manufacturing Hub
2018 has been the most exciting year in ABS history. We have opened the door to China, added amazing new talent to our board and executive team, partnered with Family Office Network and reached 48 international patents awarded and pending.
Today I am thrilled to announce another major step forward. Advanced Bifurcation Systems® is opening our global manufacturing facility for our mother-daughter coronary stenting platform. We selected a facility in Livermore, California that is located down the street from Lawrence Livermore National Laboratory in one of America’s most innovative regions.
We are in amazing company here. The region encompassing Bay Area and Silicon Valley region is the world’s top center of innovations and has one of the greatest collections of minds found anywhere. Talent is the key to fulfilling our mission and ultimately that was the most important factor in why we selected this area. We will join many other great companies in exporting American innovations from here, around the world. Ultimately, I do expect we will want to secure additional manufacturing outside the US.
The new facility will start as our global manufacturing hub for our mother-daughter stenting platform and will play a major role in our upcoming application to the United States Food and Drug Administration. The facility has its own Class 10,000 Cleanrooms which are all being certified to build and assemble the ABS product portfolio.
Heart Disease is the world’s top health problem, especially as nations age, economies develop, and diets and lifestyles change. Public and private health systems around the world struggle to provide affordable medical care on the scale needed. To start, the facility will create approximately 35-50 new jobs, but the facility has the capacity to handle very large growth. ABS’ solution is a rare, game changing solution.
Earlier this year, experts estimated that the coronary stent market will reach $10B in 2025. Bifurcation disease could be about 25% of this market. I believe that with ABS could capture a significant part of this. I believe that FDA review and market response will show that our platforms will allow more cardiologist to treat more people, more cheaply, more safely and more reliably than the current mix of stents and surgery.
My company has partnered with Family Office Networks. We are happy to be a part of their goals.
We are holding an event at Flemings Steakhouse in Newport Beach California on August 21st 2018 from noon until 2pm. I will be speaking about how ABS’s platform is the only platform that covers all bifurcations.
Please join us, you can RSVP here.
Technological Innovations Give Hope in the Fight Against Heart Disease
From apps that diagnose irregular heart rhythms to fitbits with sensors to measure heart rate, a wave of heart technological innovations has appeared as companies cash in on the battle to fight heart disease.
The question always arises of how accurate the results are from a medical point of view. When it comes to measuring blood pressure and more on devices we use every day, like smartphones, there definitely needs to be more research. For example, readings could be influenced by motion, consistent contact with the skin, etc.
Smartphone Blood Pressure Check
Last year Caltech showed that a smartphone app could accurately measure how much blood the hearts pumps with each beat. In turn, all patients had to do was hold a smartphone camera up to their neck for less than two minutes, and an algorithm in the app analyzed the information. This was found to be as accurate as doing an ultrasound.
Other Heart Technological Innovations
Artificial intelligence is changing the way cardiac disease is being handled because of the way data can be absorbed, processed and analyzed. When it comes to healthcare, this can make all the difference in the way patients are diagnosed and treated.
For instance, cardiologists are able to read and interpret the results of echo studies more quickly and efficiently. Catching heart disease early and treating it efficiently is more possible when using AI.
Our dual catheter system is another technological innovation that I hope will bring about a revolution in the way heart disease is treated. Patients will no longer have to undergo lengthy, complex operations. The interventional cardiologist will be able, and the patient will be out the same day.
At present we seem to be losing the fight against heart disease, but technological innovations could make a difference. They have the potential to change cardiac healthcare for the better by addressing current limitations.
MaRS Accepts ABS
My company, Advanced Bifurcations Systems has been accepted to join MaRS. MaRS helps bring all avenues of entrepreneurs and startups together with an extensive network of partners all together. Their goal is to bring new companies reach their their goals.
Our article written for BioSpace can be found here.
Tackling a Global Pandemic
ABS was founded because there’s a real need for improvements in the way we approach the global heart disease problem. Current methods for treating heart disease aren’t always successful. 7.4 million people die from a heart attack every year. Several new technologies could change that and our innovative new stenting platform is one of them. We hope that human clinical trials and FDA review will show that it could reduce the need for open-heart surgery and improve the quality of life for patients suffering from heart disease.
How the ABS System Works
One of the most difficult procedures for heart surgeons is trying to place stents in branched arteries. The ABS system is designed to simplify the process and replace most open-heart surgeries with a less invasive procedure that can be performed as a day surgery.
Open-heart surgery is a stressful experience for the patient and many suffer depression after their operation. A simple day procedure would reduce their anxiety and allow them to return to their daily lives without a significant recovery period.
The method works by using a dual catheter system to place stents in both the mother and daughter vessels of a branched artery at the same time. The technology is self-aligning as well, to reduce the risk of errors and it’s simple to perform. Most cardiac surgeons will be able to perform the procedure without much training.
A Major Part of the Puzzle
The ABS system isn’t the only breakthrough we hope could aid in reducing deaths from heart disease. New technologies in the areas of Artificial Intelligence, apps, and wearable devices are also part of the solution. It’s not difficult to imagine the risk of death from a heart attack being cut in half in the next decade. Technology is allowing people to live longer and healthier lives. I think that Advanced Bifurcation Systems is a major piece of the puzzle along with these other technologies.
Friendly Smiles and Helpful Hosts
I made it to Beijing and am really enjoying the city. The people here are very friendly as everyone smiles and appears very upbeat. Everywhere I go locals have been very willing to help with anything I have needed. It is a surprisingly friendly reception for such a large city.
An Ocean of Bikes – Go Ahead and Take One
Beijing is very clean and very, very busy. There are remarkably large numbers of cars, motor scooters and thousands of bikes. It sometimes feels like an ocean of bikes. Bikes sit on every corner and people just ride one and drop it off wherever their destination might take them.
I had 3 meetings this morning. All of them went well and I am excited at the scope of the opportunities in China. Heart disease is a global pandemic killing 17M people a year. In many rapidly developing economies like China, aging populations, more western diets, more dairy and red meats and more sedentary office jobs mean that we need new tools to address heart disease in all its forms.
Talent, Capital and Opportunity
Beijing has a highly skilled work force with many university educated engineers. We discussed a facility in Shenzhen with potential for a joint venture with a fund in China. Shenzhen is in southeastern China and links Hong Kong to China’s mainland.
Meeting this afternoon with State Development & Investment Corporation (SDIC). SDIC is the largest Chinese state owned investment fund and they last reported assets of over 461.7 billion RMB yuan a few years ago.
That is it from Beijing today. I have dinner tonight and will finish late. Tomorrow is Friday here and I have more meetings in the morning and then I am headed to the airport and back to LA.
Today was my third and final day in Shanghai. Tomorrow morning, I leave for Beijing. I am looking forward to seeing the city and am excited at how well the trip has gone.
Most of today I met with some great people from the global company Terumo Corporation.
Terumo is a medical device company with over $4B USD in annual sales. They have lines of business including general hospital devices and supplies such as catheters, thermometers and monitors as well as a business that produces a broad range of blood management devices and supplies. And, of course, they have a cardiac and vascular business as well.
We started out early this morning and covered everything about ABS and our platform. After a few hours we dialed in Doctor Mehran Khorsandi, ABS cofounder and chief medical officer, to cover some questions that were specific to interventional cardiology. Again, after Mehran spoke he answered their questions and left our hosts with no doubt about the ability of cardiologists to transfer to the ABS system. I look forward to follow-up meetings with Terumo at their corporate headquarters in Japan.
This was our second set of meetings with Terumo. We last met with them at the JP Morgan in California a few weeks ago. We also met today with Fosun Pharma and Lilly Asia Ventures. Both meetings were good, and their representatives were well informed on the Asian market. We discussed the regional potential for companies like ABS. Heart disease is a major global problem and kills over 47,000 people a day. So, the hard work by the people at companies like Advanced Bifurcation, Terumo and Fosun Pharma is important to everyone.
Today was a very busy day and the jet lag is catching up with me a bit.